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Abstract
Background: In the United Kingdom, non-medical prescribing (NMP) has been identified as one way to improve
healthcare quality and efficiency. Healthcare organisations are charged with overseeing the clinical governance of
NMP and guidance recommends the identification of a lead director to be responsible for its implementation.
While over twelve million items are prescribed each year by the 50,000 qualified NMPs its uptake is inconsistent.
Several studies have explored the barriers to NMP at a practice level, however little is known about the role the
NMP lead and the implementation of NMP from an organisational perspective. The aim of this research was to
explore the role of the organisational NMP lead across a range of practice settings within one Strategic Health
Authority (SHA) and consider the development of NMP from a multi-organisational perspective.
Methods: Semi-structured telephone interviews with 28 NMP leads across one SHA were undertaken by a trained
qualitative researcher. Interviews addressed the purpose of the role and difficulties encountered; audiotapes were
transcribed, coded and themes were identified.
Results: The NMP lead role comprised of four main functions; communication, coordinating, clinical governance
and support. Factors hampering progress in overseeing the safe development of NMP included lack of clarity
about the NMP lead role and responsibilities, strategic support and a lack of protected time. The extent to which
clinical governance systems were in place across organisations was inconsistent. Where a strategic approach to its
development was adopted, fewer barriers were encountered and NMP was more likely to become embedded
within organisations.
Conclusions: The significant contribution that NMP leads play in embedding NMP within organisations should be
acknowledged by clearer national guidance for this role and its responsibilities. Greater standardisation and
consistency is required of clinical governance systems if quality and safety is to be ensured given the expanding
development of NMP. The extent to which NMP is in place worldwide differs. However, our findings will be of
interest to policymakers in other countries involved in the development and implementation of this role.
Background
As part of the modernisation of the United Kingdom (UK)
healthcare workforce, prescribing authority has been
extended to nurses, pharmacists, allied health professionals
(AHPs) (including radiographers, physiotherapists,
podiatrists/chiropodists) and optometrists [1,2]. Although
prescribing by non medical healthcare professionals is in
place in some countries (such as the States and Sweden)
and anticipated in others (e.g. the Netherlands) [3], non
medical prescribers (NMPs) in the UK have the most
extended prescribing rights in the world. They offer a stra-
tegic innovative solution to address capacity, quality, effi-
ciency, and effectiveness if used widely in pathway
redesign and should be considered within all service
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[2]. There are now over 50,000 NMPs across the UK. This
includes more than 30,000 community practitioner pre-
scribers with powers to prescribe from a restricted formu-
lary (mainly over-the-counter medicines and wound
dressings) and approximately 19,000 nurses [4], 2,000
pharmacists, and several hundred AHPs and around 70
optometrists [5] with an independent [2] and/or supple-
mentary prescribing [6] qualification. Over 12 million
items are prescribed each year by NMPs in primary care
[7] and the extension of prescribing rights to paramedics
and other groups of AHPs (including dieticians) is cur-
rently under consideration [8,9].
Independent Prescribing (IP) and Supplementary Pre-
scribing (SP) are two different forms of prescribing.
Through IP, nurses and pharmacists may assess, diag-
nose and prescribe independently any licensed or unli-
censed medicines with the exception of controlled drugs
(CDs). Under current legislation [3], nurses can pre-
scribe some CDs whereas pharmacists cannot. Supple-
mentary prescribing, in contrast, is a form of dependent
prescribing where the initial assessment and diagnosis is
carried out by a doctor and the medicines to be pre-
scribed are detailed in a Clinical Management Plan
(CMP) agreed between the doctor, NMP and patient.
Through SP, the NMP can prescribe any medicine
including CDs.
Learning on the NMP programme is often between
nurses, pharmacists and AHPs (optometrists undergo
separate training). The programme comprises 27 taught
days (although some programmes have a distance learn-
ing element) and 12 days in practice with a designated
medical practitioner (DMP) who is responsible for the
assessment of practice [2]. On completion of the course,
nurses and pharmacists are awarded a dual qualification
in independent and supplementary prescribing whereas
AHPs qualify as supplementary prescribers.
T h e r ei se v i d e n c ea v a i l a b l et h a tN M P sc a ni m p r o v e
the quality of care patients receive and provide services
that are both flexible and accessible to patients. For
example, patients value the interpersonal skills of nurse
and pharmacist prescribers and the longer consultations
they offer [10-14]. Improved access to medicines and
increased service efficiency are benefits attributed to
NMP by patients, NMPs, doctors and other stakeholders
[10,15,16]. Nurses and pharmacists have been shown to
be competent at assessing patients, producing appropri-
ate prescriptions, and providing patients with informa-
tion and advice about treatment and side effects
[10,17,18]. Adopting the prescribing role is reported to
increase job satisfaction, improve inter-professional col-
laboration and encourage flexible team working [10,19].
In some areas, such as nurse-led dermatology clinics,
NMP has enabled the development of new services with
less dependence on doctors [16]). However, despite
these reported benefits, the uptake and use of NMP is
inconsistent. For example, while high numbers of nurses
in general practice prescribe [20], poor uptake/and or
use has been reported by pharmacists [21], nurses work-
ing in diabetes services [22], and mental health [23].
Unsuccessful implementation of NMP is potentially
costly in terms of the time and expenses for training
individuals to prescribe [10] and failure to deliver pre-
dicted efficiency savings within services. A number of
studies have explored the barriers to NMP at a practice
level. Barriers with regards to planning for NMP include
the cost of training [10] and a lack of incentive to
undertake it [15]. The initiation of prescribing once qua-
lified can be prevented by a lack of confidence on behalf
of the prescriber, a lack of clarity over the prescribing
role, difficulties in accessing medical records and elec-
tronic prescriptions, inadequate procedures for register-
ing new prescribers and obtaining prescribing pads
[20,24-26]. Restrictions imposed by national and local
regulations and restrictions set by individual trusts,
resistance from doctors or managers, lack of access to a
prescribing budget, inadequate support, access to conti-
nuing professional development (CPD) [20,26], and
practical difficulties in implementing the CMPs neces-
sary for supplementary prescribing [27,28], can each
influence prescribing activity and its on-going use.
Guidance [2] refers to the responsibilities of organisa-
tions to develop a strategic plan for NMP and this plan
should include the identification of a lead director
responsible for the implementation of NMP within the
organisation. To ensure that NMP is used safely and effi-
ciently it should be included within organisational clinical
governance arrangements [2]. However, there is no evi-
dence available that has explored the development of
NMP from an organisational perspective. The aim of this
research was to explore the role of the organisational
NMP lead across a range of practice settings within one
Strategic Health Authority (SHA) and consider the devel-
opment of NMP from a multi-organisational perspective.
Methods
Design
A qualitative design was selected, using semi-structured
telephone interviews and framework analysis.
Participants
All NMP leads across the SHA (n = 44) were contacted
via email (with a reminder two weeks later), and invited
to participate.
Data collection
A two-part interview schedule was developed based on
previous work in the area [29,30] and comments from
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pants for details about their role (i.e. job title, whether
their role was a clinical role and if they were a prescri-
ber), if they had designated time for the lead role and
length of time in post, the number and types of prescri-
bers they covered (including area of practice/geographi-
cal area) and, if they held a database of prescribers
details, what information they stored. Participants were
then asked the extent to which safety and clinical gov-
ernance procedures were in place. The second part of
the interview asked participants about the purpose of
their role, difficulties encountered, and factors support-
ing their role.
Interviews, held at mutually convenient times and last-
ing between 25-45 minutes, were conducted between
August 2009 and December 2009.
Ethical consideration
NHS and University Ethics Committee approval for the
study was obtained. NMP leads who were interested in
participating in the study were provided with an infor-
mation sheet and given the opportunity to ask the
researchers any questions. Participants were informed
that the interview would be conducted in two parts with
part 1 recorded on paper, and part 2 audio-taped, tran-
scribed and anonymised. Consent was obtained prior to
interviews and participants were free to withdraw from
the study at any time.
Data Analysis
SPSS version 17 was used for data entry and analysis of
part 1 of the interview. Data was summarized using
descriptive statistics. Qualitative data generated in part
two of the interview were analysed using a form of fra-
mework analysis [31]. Interview transcripts were read by
two researchers who then worked together to develop a
coding framework based on a combination of emerging
themes and initial research questions. The researchers
then applied the framework to code each interview tran-
script using ATLAS ti software and then charted the
range and variety of responses under each code. Once
charted, patterns and associations in the data were iden-
tified and organised into themes. The two researchers
initially worked independently to analyse different inter-
views, meeting regularly to discuss changes to the cod-
ing framework before working together to develop the
final analysis.
Results
Twenty eight (64%) of the 44 NMP leads across the
SHA agreed to participate. They worked in hospital, pri-
mary care and mental health trusts and were responsible
for varying numbers and types of prescribers. Character-
istics of the leads and their role are summarised in table
1. Participants held a mixture of managerial and clinical
roles, eight of which were at directorate level. Fourteen
(50%) participants held a prescribing qualification. Nine-
teen (68%) reported that there was no designated time
for the role and 15 (54%) spent between 30-60 minutes
a week on it.
The role of the lead in supporting NMP
Participants reported that their role had four core ele-
ments (see table 2) each of which is explored below:
i) Information and communication
One of the main elements in which leads were involved
was two-way communication between the trust and
NMPs. Participants described how they acted as an
information conduit, disseminating information to
NMPs on legislation, policy and good practice so as to
ensure that they were kept up-to-date. They also
described how they were a point of contact for NMPs to
discuss any prescribing issues or queries and how they
fed this information back to the trust
’I think it’s (my role) to be a conduit so that informa-
tion coming into the organisation gets to all the
NMPs because they’r ea l ls od i v e r s ea n di ns om a n y
different little pockets and silos. I see my prime
responsibility is to make sure that they’re kept up to
date with any change. If I get access to information
about prescribing practice nationally or, the East of
England, I see that it gets to them.’[19]
ii) Promoting and co-ordinating
Promoting and co-ordinating NMP within the trust was
also considered to be a key aspect of the lead role as
was working to integrate and expand NMP into service
planning.
’It’s actually making sure that we are driving this
agenda, giving nurses opportunities, looking at new
ways of working, trying to improve patient care and
giving you know patients, you know benefits to
prescribing.’[5]
A number of leads felt that in order to raise the pro-
file of NMP in less developed areas, for example phar-
macist prescribing, that their involvement in decision
making at a strategic level was necessary. Liaising with
higher education providers to ensure the NMP pro-
gramme met the learning needs of their employees was
also considered to be an important aspect of the leads
role by several participants.
’to inform the pharmacy networks on regional
NMP initiatives, to provide input from a pharmacy
perspective about where pharmacist prescribing
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Yes No Not applicable
n = 28 unless otherwise stated n % n %n %
Job Title
Clinical quality & governance 4 14.3
Strategic pharmacist 3 10.7
Chief/deputy chief nurse 8 28.6
Nurse consultant/clinical nurse specialist 9 32.1
Education/workforce development 4 14.3
Is this a clinical role? 14 50 14 50
Is there designated time for NMP lead role? 9 32.1 19 67.9
Number of hours per week spent on NMP lead role? Mean 2.2
0.5-1 15 53.6 Median 1.0
1.5-3 7 25.0 Mode 1.0
>3 6 21.4 Min 0.5-Max 10
Do you have a prescribing qualification? 14 50.0 13 46.4 1 3.6
Nurse independent supplementary prescriber 12 42.9
Community practitioner prescriber 2 7.1
Do you currently prescribe? (n = 14) 8 57.1 6 43.8
How long NMP lead?
<6/12-1 year 6 21.4
2-5 years 14 50.0
>5 years 8 28.6
Area of practice?
PCT 10 35.7
NHS trust 11 39.3
Mental Health 6 21.4
PCT/NHS Trust & Mental Health 1 3.6
Geographical area?
Rural 4 14.3
Urban 2 7.1
Mixed 21 75.0
Not applicable 1 3.6
Do you hold a current database? 25 89.3 1 3.6 2 7.1
Information on database? (n = 26)
Types of prescriber 26 100
Registration details 24 85.7 2 7.1
Work setting or clinical area 23 82.1 3 10.7
If they are prescribing 18 64.3 8 28.6
If they are not prescribing 15 57.6 11 42.4
Other (CRB check, supervisor details, manager details, audit) 8
Number of prescribers lead is responsible for Range: 3 -547 Mean: 87.3
Types of prescribers covered by NMP lead
Community practitioner prescriber 18 64.3
Pharmacist independent/supplementary prescriber 21 75.0
Nurse independent/supplementary prescriber 22 78.6
AHP (podiatrist/physiotherapist/radiologist) 6 21.4
Optometrist 2 7.1
(NMP = non-medical prescribing, PCT = Primary Care Trust, NHS = National Health Service, CRB = Criminal Records Bureau, AHP = allied health professional)
Courtenay et al. BMC Health Services Research 2011, 11:142
http://www.biomedcentral.com/1472-6963/11/142
Page 4 of 10can fit into care pathways as an alternative provi-
der and to ensure that the pharmacy workforce
(being very small) is not forgotten as potential pre-
scribers for particular care pathways in different
sectors.’[11]
iii) Clinical governance
Ensuring that clinical governance systems were in place
and up-to-date was felt to be a critical part of the role
by the majority of leads as described in the quote below:
“..from an organisational perspective that we are
assured that the organisation provided a safe envir-
onment for the prescribers to prescribe in and that ...
we have systems and processes in place that would
fulfil the accountability role, the support role, the
development role.” [13]
All but one lead held an electronic database in which
they recorded the details of NMPs i.e. type of prescriber,
work setting, and whether or not the prescriber pre-
scribed. However, the extent to which this information
was recorded by NMP leads varied (see table 1). Table 3
provides a detailed summary of the extent to which
leads reported each aspect of clinical governance was in
place. Systems were reported to be in place for ordering
and distribution of the British National Formulary
(BNF) (and the Nurse Prescribers’ Formulary (NPF) for
Community Practitioners and the Drug Tariff), ensuring
NMP policies were updated and that NMPs kept
informed of relevant clinical information. However, the
extent to which systems for monitoring prescribing were
in-situ, and the degree to which practitioners were able
to access monitoring data and participate in clinical
audit and review was inconsistent. Difficulties were
reported to be encountered in monitoring private practi-
tioners (such as community pharmacists and NMPs
working in the private sector), deciding how best to gov-
ern non-active NMPs or those who seldom prescribed,
and determining responsibility for governing NMPs
employed in general practice.
iv) Support and training
A number of leads felt that their role had a supportive ele-
ment both towards NMPs and their DMPs. Several leads
were involved directly and indirectly in providing CPD to
NMPs in their trust. Whilst some leads were mainly
involved with providing information about available train-
ing, others had a more active role whereby they were
directly responsible for running training sessions in their
trust.
Table 2 Key aspects of the NMP lead role
Information and communication (n = 21)
➤ Two-way communication between trusts and NMPs (n = 21)
➤ Information conduit (n = 18)
○ a) keep up to date with national policy, legal issues & good practice
○ b) disseminate information on national policy, legal issues & good practice to NMPs
➤ Point of contact (n = 11)
Promoting and co-ordinating (n = 17)
➤ Ensuring that applicants meet NMP selection criteria (n = 11)
➤ Co-ordinate and promote NMP within trust (n = 17)
➤ Work to integrate and expand NMP in service planning (n = 10)
➤ Liaise with education providers to ensure NMP programme meets needs of employees (n = 5)
➤ At a strategic level raise awareness and profile of NMP in less developed areas of practice (n = 3)
Clinical governance (n = 22)
➤ Ensure clinical governance systems are in place and up to date (n = 22)
➤ Monitor NMP practice (n = 21)
➤ Identify and deal with NMP related governance issues (n = 22)
➤ Monitor and support those not using prescribing qualification (n = 4)
Support and training (n = 17)
➤ Support NMPs before, during and after implementation of NMP in practice (n = 17)
➤ Support supervisors of NMPs (n = 17)
➤ Provide information about continuing professional development opportunities (n = 10)
➤ Provide practical training session and support groups for NMPs (n = 10)
➤ Active support role during initial implementation of NMP into practice (n = 8)
➤ Provide broad medicines management support to all NMPs (n = 1)
(NMP = non-medical prescribing)
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Page 5 of 10’I put on half day support session updating their phy-
sical examination skills and to network amongst
themselves and we bring in...I ask them to bring a
clinical issue, something that’s happened to them
that they’d like to share.’[6]
The extent to which they were involved in these ele-
ments varied, for example under half (n = 10) of the par-
ticipants provided support and training directly to NMPs.
Strategic vision
Barriers and facilitators to the development and support
of NMP reported by leads are detailed in table 4.
The amount of difficulty encountered depended upon the
strategic approach of the trust towards NMP and the invol-
vement of the NMP lead. The extent to which organisations
had a clear strategy varied. Where a consistent strategic
approach to developing NMP was in place, greater consid-
eration was given to processes including workforce plan-
ning, the selection of candidates for prescribing training,
the provision of clinical supervision, ongoing support, conti-
nuing professional development, and organisational pre-
paration for the role in terms of procedures for registering
as a prescriber and initiating prescribing. For example, it
was a requirement by some specialist services, that those
delivering the service had the prescribing qualification. New
staff appointed to that service were therefore automatically
put forward for prescribing training:
’.....thinking more around some specialist services we
have like x condition it’s written within the service
specification that whoever is delivering that service
requires the prescribing qualification and so I’ve just
had a new person come into that team and they’ve
now put forward to go on the prescribing course.’[10]
The extent that individuals were involved in the various
lead role activities varied, but greater involvement was
instrumental in alleviating many of the barriers. For exam-
ple, involvement in the selection process ranged from no
input to stringent interviewing of all candidates. Proce-
dures for developing NMP varied: some candidates self-
selected, some were selected by their manager, and some
via strategic workforce planning (i.e. where having an
NMP qualification was written into job descriptions for
certain roles). Selection criteria also varied (e.g. some
trusts set a minimum job banding and three participants
were uncertain if criteria were in place).
’it varies across the Trust because it varies according
to the area []initially it was a case of nurses who
were interested in going forward for the qualification
would apply and then if it was appropriate they’db e
assessed, is it appropriate for their role, were they
going to be able to work to the academic level
required and then it would be... would the service
actually able to free them up for the training [] but
what we’ve done in community nursing is that
because we’ve reviewed the education pathway we’re
now making independent prescribing an essential
component of the specialist training so in the future
all nurses going forward who come out at the other
end as a Community Nursing Sister [], will have the
independent prescribing qualification.’ [20]
Table 3 The extent to which NMP leads report safety and clinical governance systems are in place
Totals exclude respondents who indicted this was not applicable to their role Yes No
n % n %
1. Is there a system in place for ordering and distribution of the BNF, the NPF for Community Practitioners and the Drug Tariff?
(n = 27)
27 100 0 0
2. Do you monitor NMP legislation and ensure that policies are updated in line with the revised legislation? (n = 26) 25 96.2 1 3.8
3. Do mechanisms exist to ensure all NMPs are kept informed of relevant clinical information, e.g. Patient Safety Notices, Drug
Alerts and Hazard Warnings? (n = 27)
25 92.6 2 7.4
4. Is there an up-to-date NMP policy in place? (n = 27) 24 88.8 3 11.2
5. Is there is a mechanism in place to ensure the selection of suitable candidates for NMP training? (n = 27) 24 88.8 3 11.2
6. Is there a system in place for the acquisition and retention of specimen signatures to identify prescribers? (n = 27) 23 85.2 4 14.8
7. Are NMPs receiving appropriate support or supervision in their prescribing role (e.g. local clinical supervision groups/learning
sets or peer-support groups)? (n = 27)
22 81.5 5 18.5
8. Do NMPs have an agreed scope of practice or equivalent and is a copy of this retained by the organisation? (n = 26) 21 80.8 5 19.2
9. Do NMPs identify and fulfil continuing professional development needs relevant to their clinical work? (n = 25) 20 80.0 5 20.0
10. Are systems for monitoring prescribing (e.g. PACT data) in place in all sectors of practice? (n = 27) 18 66.7 9 33.3
11. Are NMPs involved in the development of local formularies and guidelines e.g. drug and therapeutic committee? (n = 26) 17 65.4 9 34.6
12. Do NMPs participate in regular clinical audit and reviews of their clinical services? (n = 23) 15 65.2 8 34.8
13. Do practitioners in all areas of practice have access to monitoring data? (n = 27) 14 51.9 13 41.8
(NMP = non medical prescribing, BNF = British National Formulary, NPF = Nurse Prescribers Formulary, PACT = Prescription analysis and cost trend)
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tations with potential NMPs, and followed criteria to
select individuals with the appropriate skills and experi-
ence, said this helped identify and address problems at
an early stage and so reduce barriers to prescribing once
qualified. Providing support or requiring completion of
additional courses (e.g. on numeracy, assessment and
diagnostics, pharmacology and mental health assess-
ment) pre-empted problems during and post training.
Problems securing ongoing support, finding a DMP, and
defining NMP roles were alleviated where leads pro-
vided support and discussed expectations with new
DMPs, NMP candidates and managers.
Lack of strategic vision to develop NMP reflected a
lack of organisational support, making it hard for indivi-
d u a l st oj u s t i f yt h en e e dt ot r a i n .E q u a l l y ,a no v e r l y
restrictive selection procedure presented barriers to
expanding NMP, especially within new areas of practice.
Difficulties were reported in gaining approval to develop
NMP for candidates without a defined specialty. Five
(19.2%) participants reported they were unaware
whether NMPs had an agreed scope of practice. Defin-
ing scope of practice was particularly difficult for com-
munity pharmacists:
’If there isn’t a commissioned service available, the
primary care trust (PCT) will not provide the prescri-
ber with an NHS prescribing patch. If the training
was part of that process (commissioning), they would
obviously have less of an issue about that. But if they
were doing it off their own back, they would have to
write a business case and persuade the PCT to sup-
port that pathway.’ [11]
Agreement was easier for individuals who worked
within well-defined areas within general practice or in
Table 4 Barriers and Facilitators to non-medical prescribing
Facilitators Barriers
Justifying need
(n = 14)
❖ Trust strategy & commitment to promote and fund NMP
❖ Expectations of course and intended NMP role are
discussed with interested candidates and their DMPs. Having a
defined set of patients/conditions e.g. role as specialist nurse
❖ Lack of strategic approach in organisations
❖ Lack of support from managers & clinicians
❖ Overly restrictive trust strategy to expanding the number of
NMPs
❖ Lack of vision and/or evidence of benefits of commissioning
services in new and developing areas e.g. community based
pharmacists
Finding a
practice
supervisor (n =
18)
❖ Having an established relationship with potential DMP
❖ NMP lead support for inexperienced DMPs
❖ DMPs who have already been a mentor and have positive
experience of NMP
❖ Lack of support when developing NMP in new areas of
practice
❖ Lack of financial incentive to act as DMP
❖ NMP candidates who have to find and secure DMP support
in different setting to their usual area of practice, e.g. those
working across a number of GP practices
Preparation for
prescribing role
(n = 23)
❖ Systematic and structured approach to selecting students
for NMP training, e.g. use of national criteria
❖ Trusts who provide additional training to ensure students
have pre-requisites for NMP training e.g. numeracy training,
assessment and diagnostic training, mental health
pharmacology module
❖ Students are prepared for the prescribing programme with
respect to course content & amount of learning that is
required
❖ Having a well defined prescribing role that is agreed
between NMP and their manager
❖ Inconsistent approach to selection process ❖ Lack of
awareness (amongst candidates and managers) of NMP course
academic content and requirement
❖ Inappropriate expectations (amongst candidates, manager or
clinicians) with respect to remuneration and how prescribing
qualification will be used in practice
❖ Relevance of NMP programme to non-community based
nurses
❖ Inconsistent methods of academic assessment of NMP
between different education providers
Confidence &
ongoing support
(n = 19)
❖ Trust provision of NMP support groups, meetings and
networks
❖ NMPs receive support (from NMP lead, DMP or Peers)
during initial implementation and role transition
❖ NMPs receive ongoing support from other NMPs and their
own clinical team (including clinical supervision)
❖ Supplementary prescribing used as means to build
confidence
❖ A lack of support approach within trust
❖ Lack of understanding about, and access to appropriate CPD
for prescribing role
❖ Providing support for community & mental health based
NMPs
❖ A lack of confidence to negotiate prescribing responsibility
within mental health settings or problems defining individual
scope of practice
❖ Restrictions imposed by enforced use of supplementary
prescribing
Practicalities &
legalities (n =
11)
❖ Procedures for registering and governing NMP up-and-
running in organisation
❖ Confidence reduced by the time lag between course
completion, registration with professional body as NMP, and
implementation of role
❖ Implementing NMP across range of providers in primary &
secondary care
(NMP = non medical prescribing, DMP = designated medical practitioner, GP: general practice, CPD = continuing professional development)
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said to be well supported and actively prescribed.
Factors supporting the NMP lead role
Despite the lack of designated time for the role, leads
generally reported to be well supported within their orga-
nisations, with the exception of two leads who felt there
was a lack of strategic support for NMP within the trust.
Although a lack of guidance and support at a local and
strategic level, misunderstanding of the NMP role by
clinicians, managers or trusts acted as barriers to the
NMP lead role (see table 5), the role was supported by
several factors including knowledge and experience of
NMP, and having good relationships with directors,
members of executive teams, colleagues and pharmacists:
’Yes we have a Pharmacy Advisor who attends our
meetings, attend the non-medical prescribing meeting,
you know supports us and also give us the Prescrip-
tion Analysis and Cost Trend (PACT) data informa-
tion and analyse as to what people’sp r e s c r i b i n g
patterns are like so that we can, you know, analyse it
and then discuss it, you know groups and individuals
as to you know, what the issues are with prescribing
and also the prescribers can phone the Pharmacy
Advisors in the PCT and ask for support and infor-
mation in practice when they are prescribing’. [14]
Discussion
This study is the first to specifically explore the role of
the NMP lead from a range of practice settings and con-
sider the development of NMP from a multi-organisa-
tional perspective. We acknowledge that the study is
limited to participants from one SHA.
The findings demonstrate the important role that the
NMP lead plays with regards to supporting and oversee-
ing the development of NMP within NHS trusts. How-
ever, a lack of consistency and clarity about the function
of the NMP lead role, coupled with poor strategic sup-
port for NMP within some organisations, hampered pro-
gress. While some worked at directorate level, others
had a clinical or educational remit. A lack of dedicated
time for undertaking this role, inconsistencies in respon-
sibilities, and large variations in coverage were reported.
The number of NMPs and size of area covered impacted
on the amount of time required to carry out the role,
however these factors did not appear to have been con-
sidered by trusts when allocating lead roles. It is evident
from our findings that the NMP lead role comprises
several core functions including information and com-
munication, promoting and coordinating NMP, clinical
governance and support and training. Guidance is
required from managers with regards to these functions
and sufficient time dedicated to the role in order that
they can be successfully achieved. Those factors which
support leads in their role including good relationships
with colleagues, knowledge and experience of NMP and
trust wide issues, guidance from the SHA, and estab-
lished policies and procedures should also be borne in
mind.
Patient safety and quality care is a priority for all
health care professionals. NMPs provide a broad range
of services enabling patients’ easier access to medicines
and increase choice in accessing medicines. It is essen-
tial that this is conducted safely and effectively within
robust clinical governance frameworks [2]. Clinical gov-
ernance procedures were in place for recording prescri-
bers details, disseminating important communications,
updating policy and ordering and distributing the BNF
and related documents to prescribers. However, systems
for monitoring, clinical audit and review were not
reported to be consistently in place across all sectors of
practice. This pattern of NMP governance is similar to
that reported elsewhere [29,30]. These findings empha-
sise that development is required to support systems for
monitoring and audit and to ensure that all NMPs can
review their own prescribing data, including where
Table 5 Factors supporting the NMP lead role
Supportive Factors Areas of difficulty
￿ Good relationships with colleagues, pharmacists, members
of executive teams and directors.
￿ Knowledge of NMP
￿ Experience as a NMP
￿ Knowledge and experience of trust wide issues e.g. clinical
governance, management and legal issues
￿ Guidance from SHA
￿ Good relationships with external educational organizations
￿ Established policies and procedures for:
a) identifying the need for NMP development within the
trust,
b) rigorous selection procedure
c) clinical governance procedures for NMP
￿ A lack of leadership at both a national and strategic health authority level
￿ Misunderstanding of the NMP role by clinicians, managers or trusts
￿ Lack of support for medicines management, auditing and monitoring information on
prescribing data
￿ Lack of guidance over action to be taken over NMPs who are not prescribing, or
prescribe infrequently
￿ Poor communication, lack of support and guidance from individual trusts
￿ Lack of clarity about the duties of the NMP lead role
￿ A lack of designated time for lead role, large variations in geographical coverage,
range of NMP roles and problems integrating a range of systems
￿ Having little choice or control over the quality of education provision
￿ Achieving and maintaining attendance at trust wide NMP meetings.
￿ Finding professional support for the NMP lead role
(NMP = non medical prescribing, SHA = Strategic Health Authority)
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ties were encountered in determining governance
arrangements and monitoring for private practitioners
and NMPs in general practice. These difficulties are
likely to increase under recently proposed policy
changes [32].
Factors reported as acting as barriers to NMP includ-
ing justifying a need to prescribe, finding a practice
supervisor, preparation for the role, on-going support
once qualified, and practicalities and legalities are in-line
with those identified previously [33-35]. Consistent with
the findings of two recent studies evaluating pharmacist
prescribing [36] and prescribing in mental health [23], a
lack of clear strategy at an organisational level was a
major barrier to NMP in this study. Although difficulties
were experienced gaining support for NMP for those
working in new areas of practice and without a defined
specialty, where strategies were in place, many of these
difficulties were overcome as NMP was more likely to
become embedded within organisations (through inclu-
sion in workforce planning, selection processes, training,
support and organisational preparedness); the NMP lead
playing a significant role in each of these processes.
Conclusions
The significant contribution that NMP leads play in
embedding NMP within organisations should be
acknowledged by clearer national guidance for the role,
its responsibilities and workload. While procedures and
policy for monitoring NMP are in place within NHS
trusts, greater standardisation and consistency is
required of clinical governance systems if quality and
safety is to be ensured given the expanding development
of NMP. The extent to which NMP is in place world-
wide differs. However, our findings will be of interest to
policymakers in other countries involved in the develop-
ment and implementation of this role.
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